Open access
Oct 2026
Co-targeting CDK2 and CDK9 inhibits MYC oncogenic programs and has anti-tumor effects in CIC-rearranged sarcoma
Findings identify MYC-driven transcription as a therapeutic vulnerability in CIC -rearranged sarcoma and support combined CDK2 and CDK9 inhibition as a promising treatment strategy.
Quentin Odom-Lewis, Samantha L. Davis, Stephan Pieper et al.
· Communications Medicine · 0 citations